瀬戸内海東端に位置する河内平野の考古遺跡などから得られた完新世海水準変動と地形発達史 [論文要旨及び審査の要旨]

関西大

瀬戸内海東端に位置する河内平野の考古遺跡などから得られた完新世海水準変動と地形発達史 [全文の要約]

関西大

Processes of Radiocarbon Dating at Kansai University II : Syntheses of Li Carbide and Acetylene using a Newly-Devised Reactor

本研究には，文部省科学研究費（基盤研究A, 課題番号08401014) (平成8･9年度代表網干善教，平成10･11年度代表木庭元睛）および関西大学平成10年度学部共同研究費（木庭元晴）を使用した

A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration

We conducted a genome-wide association study (GWAS) on the outcome of anti-VEGF treatment for exudative age-related macular degeneration (AMD) in a prospective cohort. Four hundred and sixty-one treatment-naïve AMD patients were recruited at 13 clinical centers and all patients were treated with 3 monthly injections of ranibizumab followed by pro re nata regimen treatment for one year. Genomic DNA was collected from all patients for a 2-stage GWAS on achieving dry macula after the initial treatment, the requirement for an additional treatment, and visual acuity changes during the 12-month observation period. In addition, we evaluated 9 single-nucleotide polymorphisms (SNPs) in 8 previously reported AMD-related genes for their associations with treatment outcome. The discovery stage with 256 patients evaluated 8, 480, 849 SNPs, but no SNPs showed genome-wide level significance in association with treatment outcomes. Although SNPs with P-values of <5 × 10[−6] were evaluated in replication samples of 205 patients, no SNP was significantly associated with treatment outcomes. Among AMD-susceptibility genes, rs10490924 in ARMS2/HTRA1 was significantly associated with additional treatment requirement in the discovery stage (P = 0.0023), and pooled analysis with the replication stage further confirmed this association (P = 0.0013). ARMS2/HTRA1 polymorphism might be able to predict the frequency of injection after initial ranibizumab treatment